The drugmaker is expected to report an in-line second quarter. It could see shares rise to $54.
The drugmaker is expected to report an in-line second quarter. It could see shares rise to $54.
Share this Article
Recommended
The drugmaker is expected to report an in-line second quarter. It could see shares rise to $54.